rhACE2 therapy modifies bleomycin-induced pulmonary hypertension via rescue of vascular remodeling

Frontiers in Physiology

Volumn 9, Issue APR, 2018, Pages

  Rathinasabapathy, Anandharajan ^a   Bryant, Andrew J ^b   Suzuki, Toshio ^a   Moore, Christy ^a   Shay, Sheila ^a   Gladson, Santhi ^a   West, James D ^a   Carrier, Erica J ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

ACE2; Bleomycin; Mice; Pulmonary fibrosis; Pulmonary hypertension

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; BLEOMYCIN; COLLAGEN; MANGANESE SUPEROXIDE DISMUTASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; ECHOCARDIOGRAPHY; FEMALE; HEART RIGHT VENTRICLE HYPERTROPHY; HEMODYNAMICS; LUNG ARTERY PRESSURE; LUNG FIBROSIS; MALE; MOUSE; NONHUMAN; PNEUMONIA; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; VASCULAR REMODELING;

EID: 85045266323     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2018.00271     Document Type: Article

References (44)

1. Archer, S. L., Marsboom, G., Kim, G. H., Zhang, H. J., Toth, P. T., Svensson, E. C., et al. (2010). Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation 121, 2661-2671. doi: 10.1161/CIRCULATIONAHA.109.916098
2. Bowers, R., Cool, C., Murphy, R. C., Tuder, R. M., Hopken, M. W., Flores, S. C., et al. (2004). Oxidative stress in severe pulmonary hypertension. Am. J. Respir. Crit. Care Med. 169, 764-769. doi: 10.1164/rccm.200301-147OC
3. Bryant, A. J., Carrick, R. P., McConaha, M. E., Jones, B. R., Shay, S. D., Moore, C. S., et al. (2016). Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 310, L249-L262. doi: 10.1152/ajplung.00258.2015
4. Bryant, A. J., Robinson, L. J., Moore, C. S., Blackwell, T. R., Gladson, S., Penner, N. L., et al. (2015). Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis. Pulm. Circ. 5, 681-690. doi: 10.1086/683811
5. Carrier, E. J., Rathinasabapathy, A., Menon, S., Kaplowitz, M. R., Fike, C. D., and West, J. D. (2016). Mas receptor activation increases Sod2 expression in pulmonary vessels and decreases endothelial dysfunction. Am. J. Respir. Crit. Care Med. 193:A2234. Available online at: https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2016.193.1_MeetingAbstracts. A2234
6. Chen, N. Y., D Collum, S., Luo, F., Weng, T., Le, T. T., M Hernandez, A., et al. (2016). Macrophage bone morphogenic protein receptor 2 depletion in idiopathic pulmonary fibrosis and Group III pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 311, L238-L254. doi: 10.1152/ajplung.00142.2016
7. El Chami, H., and Hassoun, P. M. (2012). Immune and inflammatory mechanisms in pulmonary arterial hypertension. Prog. Cardiovasc. Dis. 55, 218-228. doi: 10.1016/j.pcad.2012.07.006
8. Fernandez, I. E., and Eickelberg, O. (2012). New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet 380, 680-688. doi: 10.1016/S0140-6736(12)61144-1
9. Ferreira, A. J., Santos, R. A., Bradford, C. N., Mecca, A. P., Sumners, C., Katovich, M. J., et al. (2010). Therapeutic implications of the vasoprotective axis of the renin-angiotensin system in cardiovascular diseases. Hypertension 55, 207-213. doi: 10.1161/HYPERTENSIONAHA.109.140145
10. Freeman, E. J., Chisolm, G. M., Ferrario, C. M., and Tallant, E. A. (1996). Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension 28, 104-108. doi: 10.1161/01.HYP.28.1.104
11. Hamada, K., Nagai, S., Tanaka, S., Handa, T., Shigematsu, M., Nagao, T., et al. (2007). Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 131, 650-656. doi: 10.1378/chest.06-1466
12. He, C., Ryan, A. J., Murthy, S., and Carter, A. B. (2013). Accelerated development of pulmonary fibrosis via Cu, Zn-superoxide dismutase-induced alternative activation of macrophages. J. Biol. Chem. 288, 20745-20757. doi: 10.1074/jbc. M112.410720
13. Hemnes, A. R., Robbins, I. M., Pugh, M. E., Brittain, E. L., Piana, R., Fong, P., et al. (2017). Preliminary safety and acute hemodynamic effects of rhACE2 in human pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 195:A7688. Available online at: https://www.atsjournals.org/doi/pdf/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts. A7688
14. Hsueh, W. A., and Wyne, K. (2011). Renin-Angiotensin-aldosterone system in diabetes and hypertension. J. Clin. Hypertens. 13, 224-237. doi: 10.1111/j.1751-7176.2011.00449.x
15. Johnson, J. A., Hemnes, A. R., Perrien, D. S., Schuster, M., Robinson, L. J., Gladson, S., et al. (2012). Cytoskeletal defects in Bmpr2-associated pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 302, L474-L484. doi: 10.1152/ajplung.00202.2011
16. Johnson, J. A., West, J., Maynard, K. B., and Hemnes, A. R. (2011). ACE2 improves right ventricular function in a pressure overload model. PLoS ONE 6:e20828. doi: 10.1371/journal.pone.0020828
17. Kalra, J., Prakash, A., Kumar, P., and Majeed, A. B. (2015). Cerebroprotective effects of RAS inhibitors: beyond their cardio-renal actions. J. Renin Angiotensin Aldosterone Syst. 16, 459-468. doi: 10.1177/1470320315583582
18. Klinger, J. R. (2016). Group III pulmonary hypertension: pulmonary hypertension associated with lung disease: epidemiology, pathophysiology, and treatments. Cardiol. Clin. 34, 413-433. doi: 10.1016/j.ccl.2016.04.003
19. Lawson, W. E., Polosukhin, V. V., Stathopoulos, G. T., Zoia, O., Han, W., Lane, K. B., et al. (2005). Increased and prolonged pulmonary fibrosis in surfactant protein C-deficient mice following intratracheal bleomycin. Am. J. Pathol. 167, 1267-1277. doi: 10.1016/S0002-9440(10)61214-X
20. Li, X., Molina-Molina, M., Abdul-Hafez, A., Uhal, V., Xaubet, A., and Uhal, B. D. (2008). Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L178-L185. doi: 10.1152/ajplung.00009.2008
21. Meng, Y., Li, T., Zhou, G. S., Chen, Y., Yu, C. H., Pang, M. X., et al. (2015). The angiotensin-converting enzyme 2/angiotensin (1-7)/Mas axis protects against lung fibroblast migration and lung fibrosis by inhibiting the NOX4-derived ROS-mediated RhoA/Rho kinase pathway. Antioxid. Redox Signal. 22, 241-258. doi: 10.1089/ars.2013.5818
22. Meng, Y., Yu, C. H., Li, W., Li, T., Luo, W., Huang, S., et al. (2014). Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-kappaB pathway. Am. J. Respir. Cell Mol. Biol. 50, 723-736. doi: 10.1165/rcmb.2012-0451OC
23. Moeller, A., Ask, K., Warburton, D., Gauldie, J., and Kolb, M. (2008). The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 40, 362-382. doi: 10.1016/j.biocel.2007.08.011
24. Mortality, G. B. D., and Causes of Death, C. (2015). Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the global burden of disease study 2013. Lancet 385, 117-171. doi: 10.1016/S0140-6736(14)61682-2
25. Mouratis, M. A., and Aidinis, V. (2011). Modeling pulmonary fibrosis with bleomycin. Curr. Opin. Pulm. Med. 17, 355-361. doi: 10.1097/MCP.0b013e328349ac2b
26. Oudiz, R. J. (2016). Classification of pulmonary hypertension. Cardiol. Clin. 34, 359-361. doi: 10.1016/j.ccl.2016.04.009
27. Passos-Silva, D. G., Brandan, E., and Santos, R. A. (2015). Angiotensins as therapeutic targets beyond heart disease. Trends Pharmacol. Sci. 36, 310-320. doi: 10.1016/j.tips.2015.03.001
28. Patel, N. M., Lederer, D. J., Borczuk, A. C., and Kawut, S. M. (2007). Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 132, 998-1006. doi: 10.1378/chest.06-3087
29. Qi, Y., Shenoy, V., Wong, F., Li, H., Afzal, A., Mocco, J., et al. (2011). Lentivirus-mediated overexpression of angiotensin-(1-7) attenuated ischaemia-induced cardiac pathophysiology. Exp. Physiol. 96, 863-874. doi: 10.1113/expphysiol.2011.056994
30. Rabinovitch, M., Guignabert, C., Humbert, M., and Nicolls, M. R. (2014). Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ. Res. 115, 165-175. doi: 10.1161/CIRCRESAHA.113.301141
31. Rathinasabapathy, A., Bruce, E., Espejo, A., Horowitz, A., Sudhan, D. R., Nair, A., et al. (2016). Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis. Br. J. Pharmacol. 173, 2859-2879. doi: 10.1111/bph.13562
32. Rey-Parra, G. J., Vadivel, A., Coltan, L., Hall, A., Eaton, F., Schuster, M., et al. (2012). Angiotensin converting enzyme 2 abrogates bleomycin-induced lung injury. J. Mol. Med. 90, 637-647. doi: 10.1007/s00109-012-0859-2
33. Richeldi, L., Collard, H. R., and Jones, M. G. (2017). Idiopathic pulmonary fibrosis. Lancet 389, 1941-1952. doi: 10.1016/S0140-6736(17)30866-8
34. Schermuly, R. T., Ghofrani, H. A., Wilkins, M. R., and Grimminger, F. (2011). Mechanisms of disease: pulmonary arterial hypertension. Nat. Rev. Cardiol. 8, 443-455. doi: 10.1038/nrcardio.2011.87
35. Shenoy, V., Ferreira, A. J., Qi, Y., Fraga-Silva, R. A., Díez-Freire, C., Dooies, A., et al. (2010). The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 182, 1065-1072. doi: 10.1164/rccm.200912-1840OC
36. Shenoy, V., Gjymishka, A., Jarajapu, Y. P., Qi, Y., Afzal, A., Rigatto, K., et al. (2013). Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am. J. Respir. Crit. Care Med. 187, 648-657. doi: 10.1164/rccm.201205-0880OC
37. Shorr, A. F., Wainright, J. L., Cors, C. S., Lettieri, C. J., and Nathan, S. D. (2007). Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur. Respir. J. 30, 715-721. doi: 10.1183/09031936.00107206
38. Sitbon, O., Jaïs, X., Savale, L., Cottin, V., Bergot, E., Macari, E. A., et al. (2014). Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur. Respir. J. 43, 1691-1697. doi: 10.1183/09031936.00116313
39. Stacher, E., Graham, B. B., Hunt, J. M., Gandjeva, A., Groshong, S. D., McLaughlin, V. V., et al. (2012). Modern age pathology of pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 186, 261-272. doi: 10.1164/rccm.201201-0164OC
40. Strawn, W. B., Ferrario, C. M., and Tallant, E. A. (1999). Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 33(1 Pt 2), 207-211. doi: 10.1161/01.HYP.33.1.207
41. Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., et al. (2002). Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277, 14838-14843. doi: 10.1074/jbc. M200581200
42. Wang, J. N., Shi, N., and Chen, S. Y. (2012). Manganese superoxide dismutase inhibits neointima formation through attenuation of migration and proliferation of vascular smooth muscle cells. Free Radic. Biol. Med. 52, 173-181. doi: 10.1016/j.freeradbiomed.2011.10.442
43. West, J. D., Carrier, E. J., Bloodworth, N. C., Schroer, A. K., Chen, P., Ryzhova, L. M., et al. (2016a). Serotonin 2B receptor antagonism prevents heritable pulmonary arterial hypertension. PLoS ONE 11:e0148657. doi: 10.1371/journal.pone.0148657
44. West, J. D., Voss, B. M., Pavliv, L., de Caestecker, M., Hemnes, A. R., and Carrier, E. J. (2016b). Antagonism of the thromboxane-prostanoid receptor is cardioprotective against right ventricular pressure overload. Pulm. Circ. 6, 211-223. doi: 10.1086/686140